Back Login to subscribe 🔔 Set Alert

RHHVF Roche Holdings AG Basel Ordinary Shares

Sector: Healthcare
Industry: Drug Manufacturers - General
15 min delay
Today's News Sentiment
Loading...
Upcoming Earnings
Loading...
RHHVF Fundamental Data
Loading...
Similar Companies
Loading...
RHHVF Options Chain
Put/Call Ratio
-
-
Expected Move
-
-
Max Pain
-
-
ATM Call Break-even
-
-
ATM Put Break-even
-
-
Loading options…
CALLS
Strike Last Bid Ask Mark IV Volume OI Δ Delta Θ Theta
PUTS
Strike Last Bid Ask Mark IV Volume OI Δ Delta Θ Theta
RHHVF Insider Transactions
Loading insider data…
RHHVF News
Date Headline Sentiment
Roche Licenses Rona’s ALK7-Targeting RNAi Candidate For Obesity And Metabolic Diseases, With Rona Eligible For Up To $1.06B In Milestones Plus Royalties
85.4%
Reported Saturday, FDA Accepts Genentech’s Vamikibart BLA For Uveitic Macular Edema With Approval Decision Expected By July 2027, Following Phase III Data Showing Sustained Improvements At 52 Weeks
89.55%
Roche Wins FDA Nod For Tecentriq Combination In Adjuvant Stage III DMMR Colon Cancer As 36-Month Disease-Free Survival Reaches 86% Versus 76% With Chemotherapy Alone In ATOMIC Trial
69.52%
Roche's Vabysmo Lifts Vision By 4.6 Letters In Untreated nAMD Eyes And 8.2 In DME After 12 Months In Real-World VOYAGER Data Presented At EURETINA
82.32%
Genentech's Giredestrant Plus Everolimus Cuts Risk Of Progression Or Death 44% In ITT And 62% In ESR1-Mutated ER-Positive Advanced Breast Cancer In Phase III EvERA; FDA Goal Dates Are Dec. 18 For Advanced Disease And Nov. 30 For Early-Stage Disease
81.07%
FDA Accepts Roche's Fenebrutinib NDA Under Priority Review For Relapsing And Primary Progressive MS, Backed By Phase III Data Showing 51.1%, 58.5% Relapse Reductions Vs Teriflunomide
90.96%
Roche Subsidiary TIB MOLBIOL Launches LightMix Newborn TREC/SMN1/HBB Kit To Screen Newborns For SMA, SCID And Sickle Cell Disease Simultaneously
50.54%
Roche's Sefaxersen Meets Primary Endpoint In Phase III IMAgINATION Study, Significantly Reduces Proteinuria Versus Placebo At 37 Weeks In IgA Nephropathy Patients
54.09%
Roche's Enicepatide Meets Both Primary Endpoints In Phase II Trial, Delivering Dose-Dependent Glucose And Weight Reductions In Type 2 Diabetes And Obesity Patients
93.58%
Roche Says Phase III CELESTIMO Study Meets Primary Endpoint With Clinically Meaningful Reduction In Disease Progression Risk For Follicular Lymphoma Patients
89.75%